Wyeth Halts Alzheimer’s Vaccine Trial, Drops HCV Candidate
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Wyeth and development partner Elan have suspended a trial involving the Alzheimer's vaccine ACC-001 in Phase II, following reports of skin lesions in one patient